Category: Compliance Monitoring

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

In the first quarter of the year, Olympus Corp., the United States’ largest distributor of endoscopes and related equipment, agreed to pay $623.2 million to resolve criminal charges and civil claims relating to a scheme to pay kickbacks to doctors and hospitals. It was further announced that a subsidiary of the distributor will pay $22.8 […]

The U.S. Department of Justice (DOJ) doubled the penalties for False Claims Act (FCA) violations on the 1st of August, 2016. As of August 1, the penalties have been increased from $5,500 to $11,000 per claim to $10,781.40 and $21,562.80 per claim. Of course, the threat of triple damages remains in place. Announced back in […]

qordata announces the addition of the latest 2015 Open Payments data that was made available by CMS to its software. Headquartered in Princeton, New Jersey, qordata provides analytics software to pharmaceutical companies to help them get more out of their open payments data and to ensure that it complies with all data submission requirements set […]

Pharmaceutical and device companies have recently reported their 2015 payments and other transfers of value that were made to physicians and teaching hospitals as necessitated by the Sunshine Act. Each time the reporting deadline of March 31 comes up, pharmaceutical companies are faced with the fear that they will miss something. And while there are […]

Since 2013, Federal regulators have stepped up scrutiny of the relationships between pharmaceutical manufacturers and healthcare providers. Considering the potential fines that are in place, this isn’t a time when companies can sit back complacently. Instead, they must dedicate this time to verifying the accuracy of their data and reporting systems so they can identify […]

Government agencies are increasingly using publicly available data sets in support of their allegations against pharmaceutical and device manufacturing companies. A recent example is the government’s allegation of kickbacks against Insys Therapeutics, Inc. and their use of both Open payments and Medicare Part D data. Managing the Risk of Open Payments Data CMS published the […]